• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Inhaled amphotericin B lipid complex for prophylaxis against COVID-19-associated invasive pulmonary aspergillosis.

作者信息

Soriano María Cruz, Narváez-Chávez Gabriela, López-Olivencia Marina, Fortún Jesús, de Pablo Raúl

机构信息

Intensive Care Department, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Carretera de Colmena Viejo, km 9,100, 28034, Madrid, Spain.

Infectious Diseases Department, Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.

出版信息

Intensive Care Med. 2022 Mar;48(3):360-361. doi: 10.1007/s00134-021-06603-y. Epub 2021 Dec 23.

DOI:10.1007/s00134-021-06603-y
PMID:34940907
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8697542/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeee/8697542/3ddbd0b8a46e/134_2021_6603_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeee/8697542/3ddbd0b8a46e/134_2021_6603_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eeee/8697542/3ddbd0b8a46e/134_2021_6603_Fig1_HTML.jpg

相似文献

1
Inhaled amphotericin B lipid complex for prophylaxis against COVID-19-associated invasive pulmonary aspergillosis.吸入用两性霉素B脂质复合体用于预防新型冠状病毒肺炎相关侵袭性肺曲霉病
Intensive Care Med. 2022 Mar;48(3):360-361. doi: 10.1007/s00134-021-06603-y. Epub 2021 Dec 23.
2
Aerosolized Lipid Amphotericin B for Complementary Therapy and/or Secondary Prophylaxis in Patients with Invasive Pulmonary Aspergillosis: A Single-Center Experience.雾化脂质两性霉素 B 作为侵袭性肺曲霉病患者的补充治疗和/或二级预防：一项单中心经验。
Mycopathologia. 2019 Apr;184(2):239-250. doi: 10.1007/s11046-019-00331-0. Epub 2019 Mar 22.
3
Inhaled voriconazole for prevention of invasive pulmonary aspergillosis.吸入伏立康唑预防侵袭性肺曲霉病
Antimicrob Agents Chemother. 2009 Jun;53(6):2613-5. doi: 10.1128/AAC.01657-08. Epub 2009 Mar 16.
4
Mixed mold infection with and in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient.一名严重急性呼吸综合征冠状病毒2（SARS-CoV-2）患者合并 和 的混合霉菌感染。 （你提供的原文中“ 和 ”部分内容缺失，请补充完整以便更准确翻译）
Infect Dis Now. 2021 Oct;51(7):633-635. doi: 10.1016/j.idnow.2021.01.010. Epub 2021 Jan 27.
5
Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature.伏立康唑、泊沙康唑和卡泊芬净预防和治疗侵袭性曲霉病的文献复习。
Eur J Med Res. 2011 Apr 28;16(4):145-52. doi: 10.1186/2047-783x-16-4-145.
6
Combination antifungal therapy for invasive pulmonary aspergillosis.侵袭性肺曲霉病的联合抗真菌治疗
BMJ Case Rep. 2012 Dec 14;2012:bcr2012007824. doi: 10.1136/bcr-2012-007824.
7
Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient.COVID-19 相关侵袭性肺曲霉病合并肾移植受者。
Transpl Infect Dis. 2021 Apr;23(2):e13501. doi: 10.1111/tid.13501. Epub 2020 Nov 29.
8
Amphotericin B nebulisation for invasive pulmonary aspergillosis prophylaxis: the conflict of ideality and reality.雾化两性霉素B预防侵袭性肺曲霉病：理想与现实的冲突
Int J Antimicrob Agents. 2017 Feb;49(2):263-264. doi: 10.1016/j.ijantimicag.2016.11.007. Epub 2016 Dec 2.
9
Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.去氧胆酸盐两性霉素B、两性霉素B脂质复合物和脂质体两性霉素B对烟曲霉的药效学
Antimicrob Agents Chemother. 2015 May;59(5):2735-45. doi: 10.1128/AAC.04723-14. Epub 2015 Feb 23.
10
Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis.腹腔注射米卡芬净与雾化脂质体两性霉素B联合抗真菌治疗对小鼠侵袭性肺曲霉病的疗效
Antimicrob Agents Chemother. 2009 Aug;53(8):3508-10. doi: 10.1128/AAC.00285-09. Epub 2009 Jun 15.

引用本文的文献

1
Fatal COVID-19-Associated Pulmonary Aspergillosis Due to Complicated By Pneumothorax: A Case Report.致命性新型冠状病毒肺炎合并肺曲霉病并气胸：一例报告
Tanaffos. 2024 Mar;23(3):308-310.
2
Efficacy and Safety of Amphotericin B Colloidal Dispersion via Nebulized Inhalation Combined with Intravenous Therapy for Invasive Pulmonary Fungal Disease: A Single-Center, Retrospective Cohort Study.雾化吸入两性霉素B胶体分散剂联合静脉治疗侵袭性肺真菌病的疗效与安全性：一项单中心回顾性队列研究
Infect Drug Resist. 2025 Jul 10;18:3415-3425. doi: 10.2147/IDR.S519105. eCollection 2025.
3
SARS-CoV-2 infection enhancement by amphotericin B: implications for disease management.

本文引用的文献

1
Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry.危重症患者新型冠状病毒肺炎相关肺曲霉病的诊断与治疗：欧洲医学真菌学联合会登记处的结果
Intensive Care Med. 2021 Oct;47(10):1158-1160. doi: 10.1007/s00134-021-06471-6. Epub 2021 Jul 16.
2
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.新型冠状病毒肺炎相关肺曲霉病诊断与临床管理特别工作组报告
Intensive Care Med. 2021 Aug;47(8):819-834. doi: 10.1007/s00134-021-06449-4. Epub 2021 Jun 23.
3
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.
两性霉素B增强严重急性呼吸综合征冠状病毒2感染：对疾病管理的启示
J Virol. 2025 Jul 22;99(7):e0051925. doi: 10.1128/jvi.00519-25. Epub 2025 Jun 4.
4
The adverse impact of cytomegalovirus infection on intensive care units outcomes in critically ill COVID-19 patients: a single-center prospective observational study.巨细胞病毒感染对危重症新型冠状病毒肺炎患者重症监护病房治疗结局的不良影响：一项单中心前瞻性观察性研究
Infection. 2025 Mar 19. doi: 10.1007/s15010-025-02499-8.
5
Posaconazole for Prevention of COVID-19-Associated Pulmonary Aspergillosis in Mechanically Ventilated Patients: A European Multicentre Case-Control Study (POSACOVID).泊沙康唑预防机械通气患者新型冠状病毒肺炎相关肺曲霉病：一项欧洲多中心病例对照研究（POSACOVID）
Mycoses. 2025 Jan;68(1):e70023. doi: 10.1111/myc.70023.
6
Study protocol: A randomized, double-blind, placebo-controlled trial of isavuconazole prophylaxis for the prevention of covid-19-associated pulmonary aspergillosis.研究方案：一项关于isavuconazole预防新冠病毒相关肺曲霉病的随机、双盲、安慰剂对照试验。
Contemp Clin Trials Commun. 2024 May 17;39:101310. doi: 10.1016/j.conctc.2024.101310. eCollection 2024 Jun.
7
Severe mold fungal infections in critically ill patients with COVID-19.COVID-19 重症患者的严重霉菌真菌感染。
Future Microbiol. 2024 Jun 12;19(9):825-840. doi: 10.2217/fmb-2023-0261. Epub 2024 May 31.
8
Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease.新型抗真菌药物和治疗方法，以应对耐药性并改善侵袭性真菌感染的治疗结局。
Clin Microbiol Rev. 2024 Jun 13;37(2):e0007423. doi: 10.1128/cmr.00074-23. Epub 2024 Apr 11.
9
A Phase I/IIa Prospective, Randomized, Open-Label Study on the Safety and Efficacy of Nebulized Liposomal Amphotericin for Invasive Pulmonary Aspergillosis.一项关于雾化脂质体两性霉素治疗侵袭性肺曲霉病安全性和有效性的I/IIa期前瞻性、随机、开放标签研究。
J Fungi (Basel). 2024 Mar 1;10(3):191. doi: 10.3390/jof10030191.
10
Use of nebulized liposomal amphotericin B and posaconazole as antifungal prophylaxis in patients with severe SARS-CoV2 infection in intensive care unit.在重症监护病房中，使用雾化脂质体两性霉素 B 和泊沙康唑作为严重 SARS-CoV2 感染患者的抗真菌预防药物。
Infection. 2024 Aug;52(4):1459-1468. doi: 10.1007/s15010-024-02234-9. Epub 2024 Mar 26.
定义和管理新型冠状病毒肺炎相关肺曲霉病：2020年欧洲临床微生物与感染性疾病学会/国际人类与动物真菌学会研究和临床指南共识标准
Lancet Infect Dis. 2021 Jun;21(6):e149-e162. doi: 10.1016/S1473-3099(20)30847-1. Epub 2020 Dec 14.
4
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.重症监护病房患者流感相关肺曲霉病综述及病例定义建议：专家意见
Intensive Care Med. 2020 Aug;46(8):1524-1535. doi: 10.1007/s00134-020-06091-6. Epub 2020 Jun 22.
5
Airborne Aspergillus contamination during hospital construction works: efficacy of protective measures.医院建筑工程期间空气中的曲霉菌污染：防护措施的效果。
Am J Infect Control. 2010 Apr;38(3):189-94. doi: 10.1016/j.ajic.2009.07.011.